ArticleCureus2026
The Use of Aquacel® Ag for the Management of Partial-Thickness Burns in a Tertiary Center.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSilver-based dressings provide a broad range of antimicrobial and re-epithelialization benefits, making them beneficial for the rapid regeneration of wounds. Their benefits have been observed for the management of burns, in particular Aquacel® Ag, and they display antimicrobial, cosmetic, and cost-effective enhancements in the clinical setting. These characteristics provide great potential for Aquacel® Ag use in hospitals with high patient loads, such as Salmaniya Medical Complex in Bahrain.
objectiveThis study investigates the efficacy of Aquacel® Ag relative to 1% silver sulfadiazine for the management of partial-thickness burns across multiple parameters, with the goal of encouraging the establishment and implementation of guidelines that incorporate Aquacel® Ag as a key intervention in the management of partial-thickness burns. DESIGN AND
methodsThis retrospective cohort study gathered data on various demographic and burn-progression parameters, including patients' age, total body surface area, days of hospital admission, and burn swab culture. The study has been carried out at the Salmaniya Medical Complex, Bahrain. The primary outcomes assessed were infection rates and the number of days between dressing changes.
resultsThe mean duration of inpatient admission was significantly longer in the silver sulfadiazine-treated group, 12.43 ± 11.291 days, than in the Aquacel® Ag group at 4.97 ± 5.195 days (p<0.001). Additionally, the rates of positive burn swabs were significantly higher in the 1% silver sulfadiazine group than the Aquacel® Ag group, at 64.3% and 7.8%, respectively (p<0.0001).
conclusionThese findings encourage the establishment and implementation of guidelines incorporating Aquacel® Ag as a key intervention in the management of partial-thickness burns in inpatient and outpatient settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.